

Versican Plus DHP lyophilisate and solvent for suspension for injection for dogs

Authorised

- Canine parvovirus, type 2b, strain CPV-2b Bio 12/B, Live
- Canine adenovirus 2, strain CAV-2-Bio 13, Live
- Canine distemper virus, strain CDV Bio 11/A, Live

Product identification

Medicine name:

Versican Plus DHP lyophilisate and solvent for suspension for injection for dogs
Versican Plus DHP

Active substance:

Canine parvovirus, type 2b, strain CPV-2b Bio 12/B, Live
Canine adenovirus 2, strain CAV-2-Bio 13, Live
Canine distemper virus, strain CDV Bio 11/A, Live

Target species:

Dog

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Canine parvovirus, type 2b, strain CPV-2b Bio 12/B, Live
19953.00 50% tissue culture infectious dose / 1.00 Dose

Canine adenovirus 2, strain CAV-2-Bio 13, Live
3981.00 50% tissue culture infectious dose / 1.00 Dose

Canine distemper virus, strain CDV Bio 11/A, Live
1259.00 50% tissue culture infectious dose / 1.00 Dose

Pharmaceutical form:

Lyophilisate and solvent for suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AD02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Finland

Package description:

(ID2): 1 Box with (50 Vial (Glass) with 1 Dose and 50 Vial (Glass) with 1 ml) (50.0 Dose, 50.0 ml)

(ID1): 1 Box with (25 Vial (Glass) with 1 Dose and 25 Vial (Glass) with 1 ml) (25.0 Dose, 25.0 ml)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)

Marketing authorisation holder:

Zoetis Animal Health ApS

Marketing authorisation date:

3/11/2016

Manufacturing sites for batch release:

Bioveta a.s.

Responsible authority:

Finnish Medicines Agency

Authorisation number:

33345

Date of authorisation status change:

3/11/2016

Reference member state:

Germany

Procedure number:

DE/V/0267/001

Concerned member states:

Belgium Bulgaria Cyprus Denmark Finland Greece Hungary Italy Lithuania
Luxembourg Netherlands Norway Poland Portugal Romania Spain Sweden
United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)

Published on: 14/02/2022

[Download](#)

Combined File of all Documents

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

2613563-paren-20251101.pdf